Myelin transcription factor 1 (Myt1) is one of the three vertebrate C2HC-type zinc finger transcription factors that include Myt1 (Nzf1), Myt1L (Png1), and Myt3 (Nzf3, St18). All three paralogs are widely expressed in developing neuronal cells. Yet their function for mammalian development has not been investigated directly. Here we report that only Myt1 is expressed in the embryonic pancreas, in both endocrine progenitors and differentiated islet cells. Myt1 À/À animals die postnatally, likely due to confounding effects in multiple tissues. The endocrine tissues in the embryonic Myt1 À/À pancreas contained abnormal islet cells that expressed multiple hormones; although hormone levels were normal. We also created pancreas-specific Myt1 knockout mice. These mutant animals had no obvious physical defects from their wild-type littermates. Male mutant animals had reduced glucose-clearing abilities and abnormal multi-hormone-expressing cells present in their endocrine islets. In addition, they also had reduced Glut2 expression, and attenuated glucoseinduced insulin secretion in the adult islets. Surprisingly, the expression of the Myt1 paralogs, Myt1l and Myt3, was induced in the embryonic Myt1 À/À pancreas. The consequences of Myt1 inactivation in the developing pancreas could be masked by activation of its paralogs, Myt1l and Myt3. These findings suggest Myt1 is involved in proper endocrine differentiation and function.
Introduction
The endocrine islets of Langerhans contain four major cell types (a, b, d, and PP) . b cells, which account for more than 85% of the total islet cells, produce insulin. The a, d and PP cells, each account for about 5% of the islet mass, produce glucagon, somatostatin (SS), and pancreatic polypeptide (PP), respectively (Slack, 1995) . Islets also produce ghrelin from the rarer e cell type and a portion of the a cells (Heller et al., 2005; Prado et al., 2004; Wierup et al., 2004) . Together, these hormones have essential roles in regulating sugar metabolism and hormone production (Gauna and van der Lely, 2005; Qader et al., 2005) .
Recent gene knockout and cell lineage studies described fundamental molecular and cellular mechanisms underlying islet differentiation and function. At the molecular level, multiple signaling molecules and transcription factors are involved in endocrine differentiation and/or maintenance (Edlund, 2001 (Edlund, , 2002 Henseleit et al., 2005; Hill, 2005; Jensen, 2004; Kim and Hebrok, 2001; Kim and MacDonald, 2002; Polak et al., 2000; Slack, 1995; St-Onge et al., 1999; Wells and Melton, 1999) . For example, Pdx1 is required for the production of all mature pancreatic cells, although immature islet cells are present in the absence of Pdx1 (Jonsson et al., 1995; Offield et al., 1996) . Ngn3 is essential for generating all endocrine tissues (Gradwohl et al., 2000) . Arx, Nkx2.2, Nkx6, Pax4, Pax6, IA1 and several other gene products interact to produce each islet cell type (Collombat et al., , 2003 Gierl et al., 2006; Gradwohl et al., 2000; Mellitzer et al., 2006; Sander et al., 2000; Sosa-Pineda et al., 1997; St-Onge et al., 1997; Sussel et al., 1998) . At the cellular level, endocrine differentiation occurs through two phases (Jensen et al., 2000) . In the mouse before E12.5, unique glucagon or insulin producing cells are generated (Teitelman et al., 1993 ). Yet, these early endocrine cells are mitotically inactive and assumed to not contribute significantly to the mature islet population (Herrera, 2000; Jensen et al., 2000; Offield et al., 1996) . Significant mature islet cell production starts around E13.5. These newly differentiated islet cells remain mitotically inactive until E17.5, after which they undergo mitotic divisions to account for most, if not all, islet cell expansion during normal growth (Jensen et al., 2000; Wang et al., 1994 Wang et al., , 1996 . For b cell production, newly differentiated cells (insulin + ) express the transcription factor MafB. As these cells mature, they switch off MafB and turn on MafA expression (Matsuoka et al., 2003; Nishimura et al., 2006) . All endocrine islet cells are derived from Ngn3 + progenitors (Gu et al., 2002) . The progenitors for a and b cells do not co-express glucagon or insulin (Herrera, 2000) . b cells may be derived from progenitors that also express PP at an early phase of their differentiation program (Herrera, 2000) .
Vertebrates have three C2HC-type zinc finger transcription factor genes, Myt1, Myt1l, and Myt3 Bellefroid et al., 1996; Blasie and Berg, 2000; Kim et al., 1997; Kim and Hudson, 1992; Nielsen et al., 2004; Romm et al., 2005; Wrathall et al., 1998; Yee and Yu, 1998) . All three genes are highly expressed in developing neural tissues Lein et al., 2007; Matsushita et al., 2002) . Myt1 gives rise to two transcripts (Myt1a and Myt1b or Nzf2b), differing only in their 5 0 -regions, using alternative transcription initiation sites (Matsushita et al., 2002) . Myt1a and Myt1b have 6 or 7 zinc fingers, respectively. In all tissues examined, Myt1b is expressed at a much higher level than Myt1a (Gu et al., 2004; Matsushita et al., 2002) . Only one transcript is found for either Myt1l or Myt3 and each encodes a protein with 6 zinc fingers. The most conserved domains in these paralogs are the zinc fingers and the putative transcriptional regulatory domains (Bellefroid et al., 1996; Yee and Yu, 1998) . In Xenopus, xMyt1 interacts with xNgn1 to initiate neurogenesis (Bellefroid et al., 1996) . In rat cell culture, Myt1 interacts with Sin3b to regulate gene expression (Nielsen et al., 2004) . How Myt1 regulates specific target genes remains obscure.
We discovered Myt1 as a gene highly expressed in a subset of developing pancreatic cells (Gu et al., 2004) , possibly the endocrine progenitors that express Ngn3 (Gu et al., 2002) , through an unbiased screen for transcripts enriched in endocrine progenitors. Myt1 mRNA was readily detected in the endocrine progenitors and loss of Nkx6.1/ Nkx6.2 function attenuated its expression (Henseleit et al., 2005) . Both Myt1a and Myt1b transcripts were detected in the embryonic pancreas, with Myt1b being the dominantly expressed isoform (Gu et al., 2004) . Ectopic Myt1 expression in the developing chicken endodermal epithelium induced glucagon and somatostatin expression. A dominant negative Myt1 molecule inhibited endocrine differentiation in both mouse pancreas and chicken hindgut cells (Gu et al., 2004) . A Notch modifier that induced endocrine differentiation in endodermal cells also induced Myt1 expression (Xu et al., 2006) . It was also shown that Myt1 partially antagonizes Notch activity facilitating neuroendocrine differentiation (Ahnfelt-Ronne et al., 2007) . These results suggest, but do not prove, that Myt1 is involved in endocrine islet production and function.
We systematically analyzed Myt1 protein expression in the pancreatic lineages and derived both global and pancreas-specific Myt1 knockout mice. We detected Myt1 in both endocrine progenitors and differentiated islet cells. The pancreas of Myt1 homozygous mutant mice contained islet cells that co-expressed multiple hormones. Pancreasspecific Myt1 knockout male mice had reduced glucoseclearing ability, islet Glut2 expression, and glucose-induced insulin secretion (GSIS). Interestingly, during embryogenesis, the expression of Myt1l and Myt3, which were not expressed in the adult pancreas, were induced in the pancreas of Myt1 À/À mutant mice. These data suggest that Myt1 is involved in both endocrine differentiation and function, and losing Myt1 function can be partially compensated by the activation of its paralogs (i.e., Myt1I and Myt3).
Results

Myt1 is expressed in both endocrine progenitor and differentiated endocrine cells
Our previous mRNA-based studies suggest Myt1 is expressed in endocrine progenitors and mature islet cells (Gu et al., 2004) . To determine which pancreatic cell type produces Myt1, we developed antibodies for Myt1 expression analyses (Section 4).
In the developing pancreas, we detected robust Myt1 expression after E9, but not before E8.5 (Fig. 1A1 ). At this developmental stage, most Myt1 + cells also expressed Pdx1 (Fig. 1A) , suggesting their pancreatic origin. We analyzed Myt1 production in the b cell lineage. At E10.5 when insulin + cells appear, we detected Myt1 expression in all insulin + cells ( Fig. 1A2 and Table 1 ). After E10.5, Myt1 expression was maintained in a portion of the insulin producing cells. Notably, the percent of insulin + cells expressing Myt1 decreased with age. For example, 91% of insulin + cells were Myt1 + at E13.5, yet only 58.6% of insulin + cells maintained detectable Myt1 production at 12 weeks-of-age (Table 1 ). Myt1 expression was also detected in the glucagon, SS, and PP-expressing cells. Yet the percentage of these hormone + cells that co-express Myt1 remains relatively constant at all the stages studied (Fig. 1B-D) . Specifically, from the appearance of these hormones to three month of age, about 95% hormone + cells co-express Myt1 (Table 1 ). These data suggest that the mature b cells are a heterogeneous population, whereas the other endocrine cell types are relatively uniform.
In the mouse pancreas, robust Ngn3 expression is detectable at E10.5, peaks at E15.5, and then is undetectable after birth. In all stages, Ngn3 is not detectable in hormone-expressing cells, demonstrating that Ngn3 can be used as an endocrine progenitor marker (Jensen et al., 2000; Schwitzgebel et al., 2000) . We utilized two antiNgn3 antibodies, a monoclonal mouse anti-Ngn3 and a guinea pig anti-Ngn3 (Seymour et al., 2007) , to examine whether Myt1 is expressed in Ngn3 + cells. Both antibodies showed Myt1 expression partially overlapped with Ngn3 (Fig. 2) . We found significantly more pancreatic cells expressing Myt1 than Ngn3 at all stages examined (E10.5, E13.5, and E15.5; Table 2 ). These data suggest that a portion of the Myt1-expressing cells are endocrine progenitors. Myt1 expression could be turned on in cells that transiently express Ngn3. Yet Myt1 expression is maintained in these same cells, even after Ngn3 expression is switched off. This result is further supported by the findings that Myt1 expression overlaps with expression of Isl1, MafA, MafB, and Pax6, which label different endocrine progenitor or islet cell types (Supplementary data Fig. 1 ).
Myt1 is the only paralog expressed in the developing pancreas
The detection of Myt1 in both endocrine progenitor and differentiated islet cells suggests that Myt1 might participate in endocrine differentiation/function. To determine whether Myt1 is the only paralog involved in endocrine islet development, we examined Myt1l and Myt3 expression by in situ hybridization in E13.5, E14.5, and E15.5 pancreata. Although Myt1l and Myt3 were detected in some cells within mesenchymal tissues that surround the gut epithelium [which were probably neuronal cells , Fig. 3D , E and data not shown], their expression in the developing pancreas was not detectable ( Fig. 3 and data not shown), suggesting that Myt1 is the only family member likely involved in mouse pancreatic development.
Loss of Myt1 function results in abnormal endocrine differentiation
We derived a conditional Myt1 knockout allele (Myt1 fl ) to directly examine the role of Myt1 in islet cell development and function. We flanked the 91 base-pair exon common to both Myt1 transcripts (#3 exon of Myt1a or #9 exon in Myt1b, Fig. 4A -C) with tandem LoxP sites to simultaneously inactivate Myt1a and Myt1b by Cre-mediated recombination. The mutant allele introduces a frame shift that should produce truncated Myt1a and Myt1b peptides that either have no similarity to any known protein or with a single zinc finger, respectively. Sox2-Cre animals (Hayashi et al., 2002) were used to delete the floxed exon, generating the loss-of-function Myt1 allele (Myt1 À ) in the germ line. Homozygous mutant animals displayed no visible abnormality yet died immediately after birth. The diaphragm of Myt1 À/À mutant mice was not properly innervated ( Supplementary Fig. 2 ); these mutants are likely to have died due to failure to begin breathing. Because these diaphragm-related defects could be readily scored, we determined whether the Myt1 À allele had a dominant negative effect: if the mutant Myt1 products had a dominant negative effect, we would expect to find abnormal diaphragm innervation or reduced viability in heterozygous animals. Myt1 +/À diaphragms were innervated similar to wild-type animals ( Supplementary Fig. 2 ). To date, we obtained 156 wild-type and 329 heterozygous adult animals but no homozygous animals survived beyond 
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birth. This Mendelian ratio demonstrates one mutant allele does not affect viability. We further analyzed the Myt1 message levels in the wild type, Myt1
, and Myt1 À/À pancreata using in situ hybridization and semi-quantitative RT-PCR. The cRNA probe, derived from the full-length Myt1 cDNA (see Section 4), recognized both wild type and mutant Myt1 mRNA. Results show that mutant Myt1 mRNA level is reduced by more than 4-fold ( Fig. 4D , E, and F), making Myt1 À unlikely to be a dominant negative allele.
We examined the expression of insulin, glucagon, SS, and PP in Myt1 À/À pancreata at E10.5, E13.5, E15.5, and E18.5. Surprisingly, the expression levels of these hormones were not significantly different between wild-type and homozygous mutant littermates, as assayed by the number of hormone + cells, the relative fluorescence intensity within each hormone-expressing cell, or the total hormone (insulin and glucagon) content within each pancreas (Supplementary Fig. 3 and data not shown). Consistent with these findings, the number of Ngn3 + endocrine progenitors, as well as the Ngn3-expression levels within individual cells in wild type, heterozygous, and homozygous mutant embryos at E10.5, E13.5, and E15.5 did not vary neither (Supplementary Fig. 4) .
When assayed together, the mutant endocrine compartment contained a substantial percentage of cells that coexpressed insulin and PP, or SS and PP, at all stages, including E15.5 and E18.5 (Fig. 5A-D) , whereas other hormone co-expression combinations were not found at significant numbers (Fig. 5E , F, and data not shown). At E15.5, when PP + cells became detectable, less than 1.5% PP + cells expressed detectable insulin in wild type and Myt1 +/À pancreata. Yet 11.6 ± 2.4% (mean ± standard deviation) of PP + cells expressed insulin in Myt1 À/À pancreata. Similarly, E15.5 Myt1 À/À pancreata contained 19.9 ± 3.1% PP + cells that expressed SS, whereas less than 2% PP + cells expressed SS in wild type and Myt1 +/À pancreata (Fig. 5 ). At E18.5, 7.8 ± 2.1% or 21.6 ± 4.2% PP + cells also expressed insulin or SS, respectively. In wild type or Myt1 +/À pancreas, less than 3% of PP + cells expressed either insulin or SS. Student's t-test showed that the presence of these double-hormone + cells in the homozygous mutant pancreas was statistically significant (p < 0.01). At all embryonic stages, we could not detect significant number of cells that co-express glucagon and insulin ( Fig. 5E  and F ). These findings demonstrate that Myt1 is required for proper endocrine differentiation or for differentiated cells to maintain specific hormone production.
Adult Myt1
fl/À ; Pdx1-Cre pancreas has immature endocrine cells
To determine whether loss of Myt1 function compromises endocrine islet function, we derived pancreas-specific Myt1 nullizygous animals using Pdx1-Cre transgenic mice (Myt1 fl/À ; Pdx1-Cre), which inactivated Myt1 only in the Pdx1-expressing pancreatic, duodenal, and stomach cells (Gu et al., 2002) . We examined the efficiency of Myt1 deletion in these embryos and found that by E10.5 or E13.5 (n = 2), Myt1 expression in the pancreas was reduced by 60% or 88% over that of wild-type littermates, respectively. By E18.5, we did not detect Myt1 expression in Myt1 fl/À ; Pdx1-Cre pancreatic cells [(n = 2), Supplementary Fig. 5 (Fig. 6) . Specifically, wild- type islets contained 2.4 ± 0.6% PP + cells that expressed SS (n = 3), whereas Myt1 fl/À ; Pdx1-Cre islets contained 10.2 ± 5.4% PP + cells that expressed SS (n = 3). Similarly, wild-type islets contained 0.2 ± 0.1% PP + cells that expressed insulin (n = 3), whereas Myt1 fl/À ; Pdx1-Cre islets contained 4.1 ± 0.6% PP + cells that expressed insulin (n = 3). Student's t-test demonstrated that the presence of these double-hormone + cells in the Myt1 fl/À ; Pdx1-Cre pancreas was significantly different from that of wild-type pancreas (p < 0.01).
In addition to insulin + -PP + cells and PP + -SS + cells, we observed a significant number of glucagon + -insulin + cells, accounting for 2.7 ± 0.8% (n = 3) of total glucagon + cells, appeared in Myt1 fl/À ; Pdx1-Cre mutant islets. These double-hormone + cells were distributed in 8% of the islet sections. In wild-type littermates, 0.3 ± 0.1% (n = 3) of glucagon + cells expressed detectable insulin (Fig. 6) , consistent with previous findings that double-hormone + cells were rarely found in wild-type pancreas (Guz et al., 1995; Herrera, 2000) .
MafA and MafB expression reflects the maturity of pancreatic a and b cells (Nishimura et al., 2006) . If double hormone-expressing cells were immature, they might express an abnormal pattern of MafA and MafB. Indeed, MafA was detected in most wild-type b cells, but not in any of the insulin + -PP + and glucagon + -insulin + cells examined ( Fig. 6A and B) Fig. 6C and D ). These findings demonstrate these double hormone positive cells, even though they express insulin, are not mature b cells. 
fl/À ; Pdx1-Cre males have glucose intolerance and insulin secretion abnormality To investigate whether Myt1 inactivation compromises endocrine function, we examined the blood glucose levels in the adult pancreas-specific mutant animals. The Myt1 fl/À ; Pdx1-Cre mutant and wild-type mice showed no difference in their fasting glucose levels (data not shown). Yet glucose tolerance test (GTT), a more sensitive assay for general pancreas homeostatic function, revealed that Myt1 fl/À ; Pdx1-Cre male mice developed glucose intolerance when they were older than 6 weeks of age (Fig. 7A and data not shown). Consistent with this phenotype, 10-week old Myt1 fl/À ; Pdx1-Cre males displayed an attenuated glucose-induced insulin secretion: 30 min after glucose injection, wild-type animals showed a 100% serum insulin level increase while the mutant animals had only a 30% increase (Fig. 7B) . This result is consistent with the findings that Myt1 fl/À ; Pdx1-Cre mutant islets had reduced Glut2 protein levels (Fig. 7C) . The serum glucagon between wild-type and mutant animals, before and after glucose challenge, had no significant alterations (data not shown). These results suggest that reduced insulin secretion is likely responsible for glucose intolerance.
Finally, we examined the glucose-stimulated insulin secretion (GSIS) from Myt1 fl/À ; Pdx1-Cre male islets. Islets isolated from 5 weeks old mutant males, when no glucose intolerance could be detected, displayed no GSIS defects (data not shown). Seven weeks old mutant islets had no statistically significant reduction in GSIS as well. As expected, the GSIS defect in isolated Myt1 À nullizygous islets became more prominent as the males aged. At 12 weeks of age, the mutant islets had statistically significant reduction in their GSIS (Fig. 7D) . These data suggest that Myt1 is required for the development of functional islet cells. 
Myt1l and Myt3 are expressed in the Myt1
À/À mutant pancreas Our previous analyses using a dominant negative Myt1 molecule hinted that Myt1 is essential for endocrine differentiation (Gu et al., 2004) . Because neither Myt1l nor Myt3 mRNA were detected in the wild-type embryonic pancreas, we were puzzled by the weak endocrine phenotype in the Myt1 homozygous mutants. We examined whether Myt1l or Myt3 expression was induced in the Myt1 mutant pancreas, potentially compensating for the loss of Myt1 function. We found substantial levels of both Myt1l and Myt3 mRNAs in the embryonic pancreas in Myt1 global and pancreas-specific mutant pancreata at E13.5, E14.5, and E15.5 (Fig. 8 and data not shown) . Because Myt1, Myt1l and Myt3 have highly similar zinc fingers and structural domains (Yee and Yu, 1998) , this finding suggests that loss of Myt1 function may be compensated by Myt1l and/or Myt3 activity.
Discussion
Endocrine islet differentiation is a multiple-step process requiring proper expression of many factors Edlund, 2001 Edlund, , 2002 Henseleit et al., 2005; Hill, 2005; Jensen, 2004; Kim and Hebrok, 2001 ; Kim and MacDonald, 2002; Polak et al., 2000; Slack, 1995; St-Onge et al., 1999; Wells and Melton, 1999) . Although loss-of-function analyses of these genes provide a general picture on how these factors control the production of various islet cell types at the molecular level, data are less clear on how the early progenitors progress step-by-step to mature, functional specific hormone-expressing islet cells. Our data suggest Myt1 is involved in multiple steps of endocrine differentiation and function.
Myt1 GTT test results in pancreas-specific Myt1 mutants at 8 weeks of age (a p-value was marked above each time point of assay). (B) Glucose-induced insulin release in wild type and pancreas-specific Myt1 À/À mutant animals (10 weeks of age). The serum insulin levels are shown. The p-value is calculated according to the percent of serum insulin increase of each animal, before and after glucose challenge. (C) Glut2 expression in wild-type and mutant adult islets (3 month old). Insulin staining located the islet position (C3 and C4 correspond to the red Glut2 channel in C1 and C2, respectively). The two white arrows in C3 and C4 point to two acinar cells that do not express Glut2. Also note the presence of blood cells in panel C2 (appeared red) and C4 (appeared white). (D) GSIS in isolated islets from Myt1 fl/À ; Pdx1-Cre animals at two ages. Islets from wild-type animals were used as controls. The p-values are marked above each data set. Scale bars = 20 lm.
to insulin and/or SS-producing cells in the mature islets. Yet the insulin + -PP + and PP + -SS + cells could not be detected in the wild-type pancreas because they might quickly turn off PP expression as they become b and/ or d cells. Loss of Myt1 function might slow down this process and allow detection of these intermediate cells.
Existing data support this possibility. At least a portion of the adult b cells arise from a PP-expressing progenitor population (Herrera, 2000) . Whether the SS-expressing d cells could also come from these precursors was not reported. A second possibility of why insulin + -PP + and PP + -SS + cells exist in Myt1 À/À mutant embryos is that Myt1 is required during the acquisition or maturation of the b or d cell to repress PP cell fate. For example, loss of Pax4 function abolishes b and d cell production, yet boosts a cell generation . Loss of Arx function results in ablation of a cells with concomitant increase in b and d cells (Collombat et al., , 2003 . In these reports, cells that co-express more than one hormone were not reported. A third possibility is that Myt1 is involved in PP cell differentiation. In this case, loss of Myt1 function results in failure of PP cell maturation and leaky expression of other endocrine hormones. A temporally controlled PP cell marking experiment would provide clarity. (Konstantinova et al., 2007) . Alternatively, Myt1 could be required for Glut2 expression and maintenance in mature b cells. Thus, inactivating Myt1 results in the gradual loss of Glut2 in the mutant islets and subsequent glucose intolerance.
The weak pancreatic phenotype in the Myt1 mutants could be due to the compensation of Myt1l and Myt3. These paralogs have highly conserved DNA binding and transcription regulatory domains . Although the expression of these two genes were not detected in the wild-type embryonic pancreas, high levels of Myt1l and Myt3 messages were present in Myt1 À/À mutant pancreas. A triple mutant, including Myt1, Myt1l and Myt3, is likely required to fully decipher the role of these transcriptional regulators in endocrine differentiation, maintenance, and function. Lastly, how the Myt1 protein level in the embryonic pancreas regulates the expression of Myt1l and Myt3 is a subject requiring further investigation. Results from these further studies could potentially reveal a feedback compensation mechanism that allows for robust endocrine tissue regeneration under physiological stress, and therefore provides another venue for regeneration-based diabetes therapy. 
Experimental procedures
Mouse strains and care
Mouse husbandry and genotyping were performed following standard protocols. Mouse care followed protocols (M/03/363 and M/03/354) approved by the Vanderbilt Medical Center IACUC. For embryonic staging, vaginal plug appearance was counted as embryonic day 0.5 (E0.5). For routine mouse embryo production, the CD1 mouse strain was utilized (Charles River Laboratories, Inc. Wilmington, MA). For initial knockout mice production, C57BL/6 strain was used (Charles River Laboratories, Inc. Wilmington, MA). Subsequent strain maintenance and crosses utilized CD1 mice. Flpe (used to delete the selection marker in the targeted allele), Pdx1-Cre and Sox2-Cre mice were previously reported (Dymecki, 1996; Gu et al., 2002; Hayashi et al., 2002) .
Generation of Myt1 antibodies
To produce Myt1 antibodies, an open reading frame encoding Myt1 amino acid residues 109-298 (as numbered in mKIAA0835) was fused with that encoding a maltose binding protein (New England Biolabs, Beverly, MA). The fusion protein was purified and used as an antigen. This portion of the Myt1 peptide will be deleted in the mutant Myt1 allele. Antibody production in rabbits was performed by Strategic Bio-solutions (Newark, DE). The specificity of the antibodies was shown by the lack of positive signals in Myt1 À/À mouse tissues ( Supplementary Fig. 5 ).
In situ hybridization and immunohistochemistry/ immunofluorescence
In situ hybridization and immunostains followed established protocols. Briefly, mouse tissues were fixed in 4% paraformaldehyde overnight at 4°C or 4 h at room temperature. For in situ hybridization, tissues were prepared as 6 lm paraffin sections. All cRNA probes were made using cDNA clones as templates. The Myt1 cDNA (#LDN 147) was a gift from L. Hudson . This cDNA clone was digested with XhoI and transcribed with T7 RNA polymerase. The Myt1l (#6844118) and Myt3 (#5366688) cDNA clones were purchased from Open Biosystem (Huntsville, AL). These cDNA clones were digested with Sal I or Avr II and transcribed with T3 or T7 RNA polymerase for cRNA probe production, respectively. For immunostaining, either frozen or paraffin sections were utilized. Primary antibodies used: guinea pig anti-insulin, goat antic-peptide (recognizing the same cells as anti-insulin antibodies), and guinea pig anti-glucagon (Dako, Carpinteria, CA), rabbit anti-glucagon, rabbit anti-SS, goat anti-SS and guinea pig anti-PP (Invitrogen, Carlsbad, CA). Rabbit anti-Glut2 (Chemicon, Temetula, CA). Rabbit anti-MafA and MafB, gifts from R. Stein (Matsuoka et al., 2004) . Goat anti-Pdx1, a gift from C. Wright. Mouse anti-Ngn3 (F25A1B3), Hybridoma Bank, Iowa, IA. Guinea pig anti-Ngn3, a gift from M. Sander (Seymour et al., 2007) . Secondary antibodies used: FITC-conjugated donkey anti-rabbit IgG; Cy3-conjugated donkey anti-rabbit IgG; Cy3-conjugated donkey anti-mouse IgG, Cy3-conjugated donkey anti-guinea pig IgG, Cy3-conjugated donkey anti-goat (Jackson Immunoresearch, West Grove, PA). Cy5-conjugated donkey anti-rabbit IgG, Cy5-conjugated donkey anti-guinea pig IgG (Chemicon, Temetula, CA). For all antibodies, a1:500-1:2000 dilution was used, depending on the amount of tissue on each slide.
Myt1 targeting constructs and animal derivation
The targeting vector pGKNeo-DTA was a gift from A. McMahon (Zhang et al., 2001) . This vector contains a pBluescript KSII backbone, a diphtheria toxin A subunit (DTA) as negative selection marker, and a FRT-flanked pGKneo gene as a positive selection marker (Zhang et al., 2001) . A genomic fragment flanking the third exon of Myt1a was PCRamplified, sequenced, and cloned into the FseI site of the vector. The primers used were: forward: 5 0 -aggccggccaaagattaaagtttagag-3 0 and reverse: 5 0 -aggccggccctaccatgccccagcttaat-3 0 . The template was BAC #519N6 in library RPCI22, purchased from Children's Hospital of Oakland, Oakland, CA (Warming et al., 2005 0 -gaattcaattcccagcaaccaca-3 0 . Targeted ES cells were utilized to derive chimera mouse following standard procedure. After mouse line establishment, Flpe mice were used to delete the FRT-flanked pGK-Neo selection cassette (Dymecki, 1996) 0 . Expected length of wild-type fragment: 608 bp, mutant fragment: 517 bp. After RT-PCR, the intensities of the bands were quantified using BIOQUANT true-color windows system (R & M Biometrics, Nashville, TN). Gene targeting was performed using TL1 ES cells and three correctly targeted clones were identified from 219 colonies screened. Blastocyst microinjections were performed by the Vanderbilt Transgenic/ ES Cell Shared Resource, following standard procedures.
Glucose tolerance test and in vivo insulin secretion assay
GTT followed published procedure (Lammert et al., 2003) . Briefly, after overnight fasting (16 h), mice were injected intraperitoneally with glucose at 2 g per kg body weight. Blood glucose was monitored with a compact glucose analyzer (BD/Medtronic MiniMed Blood Glucose Monitor) at different time points after glucose administration. For insulin secretion assay, blood samples were taken before or 30 min after glucose injection. Serum insulin levels were assayed using the Elisa assay kit from Linco following manufacturer-recommended protocol (St. Charles, MO).
Islet isolation and glucose-stimulated insulin secretion assay (GSIS)
Pancreatic islet isolation was by collagenase perfusion (Gu et al., 2004) . Batches of 10-15 hand-picked islets of similar size were incubated in RPMI 1640-10% fetal calf serum at 37°C for overnight. These islets were washed and incubated in 1 ml Krebs-Ringer Hepes-buffered saline in 2.8 mM glucose at 37°C for 30 min and then transferred to 1 ml Krebs-Ringer Hepes-buffered saline in 20 mM glucose for another 30 min. Supernatants were collected for insulin assay. Islets were extracted for total insulin assay. Insulin secretion was calculated as percent of insulin released within the 30 min glucose stimulation. All assays utilized triplicate samples.
Confocal microscopy for protein expression and statistical analysis
All fluorescent images in the figures were from confocal microscopy. Typically, optical sections at 0.4-0.6 lm intervals were taken. A single or a projection of two adjacent optical sections was used for a high quality image. All confocal parameters were kept consistent throughout our experiments. For quantification, we utilized BIOQUANT true-color windows system (R & M Biometrics, Nashville, TN). This system assays both cell number and fluorescence intensities (Zhang et al., 1997) . The hormone amount quantified using this approach matched well with our Elisa-based total insulin or glucagon assay data from E18.5 embryonic pancreas.
For Myt1 staining, 10-15 lm frozen sections were used. For Glut2 expression or co-hormone expression analysis, 4-8 lm paraffin sections were used. For co-hormone expressing cell quantification at E15.5 and E18.5, adjacent 10 lm frozen sections were separated onto groups of three slides, with one staining for glucagon/insulin, one for insulin/PP, and one for PP/SS. Co-stained cells were counted on optical sections at 6 lm apart. Two optical sections from each tissue section were counted, and all tissue sections from each E15.5 pancreas were analyzed. A third of all tissues from each E18.5 pancreas were counted (to ensure correct representation of the samples, three adjacent sections were collected onto three individual slides. Then the next six sections were skipped before further tissue collection). For quantification in adults, each pancreas was cut into 25-30 small pieces and embedded into a single paraffin block. One of every four 4 lm sections was collected, with sets of three being mounted onto groups of three slides for glucagon/insulin, insulin/PP, and SS/PP staining respectively. Slides were then counterstained with DAPI and co-stained cells were scored using a Carl Zeiss Axioplan 2 fluorescence microscope. At least 25 sections were scored for each hormone combination in each pancreas. Statistical analyses utilized standard Student's t-test. A p-value of 0.05 or better was considered significant. All quantification data were presented as (mean ± standard deviation).
